Online Webinars

Previous Webinars

Dec 6, 2016

Late Breaking Data from the Society for Immunotherapy of Cancer 2016

Immunotherapies have improved patient responses and survival, though not all patients benefit. Effective biomarkers may help improve outcomes. Durvalumab is a human IgG1 monoclonal antibody that inhibits programmed death ligand-1 (PD-L1) binding to programmed death-1 and B7.1/CD80, restoring antitumor immunity. PD-L1 expression on tumor or tumor-infiltrating immune cells measured manually...
View Full Event Post
Oct 18, 2016

Tissue Collection Standards Determine the Future of Precision Medicine

As most compounds target specific cancer pathways, identification of pathways and their potential role as drivers for cancer growths in the individual tumor has become an attractive approach for prediction of drug response. Mutation analysis of cancer relevant genes has become the most widely used approach because DNA is a...
View Full Event Post
Jul 19, 2016

Integrated Tissue Phenomics® and Big Data for Biomarker Discovery and Test Development

Histological phenotypes generally play an essential role in diagnostics, but in particular in oncology there is a growing need for selecting the right patients for the right treatments based on information derived from tissue slides. Oncology is a rapidly evolving field with many new treatment methods being discovered. To finally...
View Full Event Post
Jun 27, 2016

Tissue Phenomics® at work for immuno-oncology and transplantation medicine

Immuno-oncology and transplantation medicine share the medical need for robust, immune cell-based biomarkers extracted from tissue biopsies. In an interdisciplinary approach, the Tissue Phenomics methodology is applied to mine clinically annotated image data. We provide proof-of-concept that spatial distribution of immune cells can provide valuable hints towards novel transplantation biomarkers....
View Full Event Post